Evaxion A (EVAX) Total Non-Current Liabilities (2021 - 2025)
Evaxion A (EVAX) posted Total Non-Current Liabilities of $7.1 million for Q4 2025, down 34.76% on a QoQ basis from $10.9 million in Q2 2025, and down 27.2% year-over-year from $9.8 million in Q4 2024.
Evaxion A (EVAX) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Evaxion A's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $7.1 million for Q4 2025.
- Quarterly Total Non-Current Liabilities fell 27.2% year-over-year to $7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.1 million (down 27.2% YoY) and the FY2025 annual result came in at $7.1 million, down 27.2% from the prior year.
- Total Non-Current Liabilities was $7.1 million for Q4 2025 at Evaxion A, down from $10.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $10.9 million in Q2 2025 and bottomed at $1.0 million in Q2 2021.
- A 5-year average of $7.5 million and a median of $9.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 819.77% — and 2025, when it decreased 27.2%.
- Evaxion A's Total Non-Current Liabilities stood at $3.4 million in 2021, then soared by 192.68% to $10.0 million in 2022, then gained by 5.76% to $10.5 million in 2023, then declined by 7.26% to $9.8 million in 2024, then slipped by 27.2% to $7.1 million in 2025.
- Business Quant data shows EVAX's Total Non-Current Liabilities at $7.1 million in Q4 2025, $10.9 million in Q2 2025, and $9.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Evaxion A | 25.44 Mn | 25.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.11 Mn |
| Jun 30, 2025 | 10.90 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Jun 30, 2024 | 10.16 Mn |
| Dec 31, 2023 | 10.53 Mn |
| Jun 30, 2023 | 10.17 Mn |
| Dec 31, 2022 | 9.96 Mn |
| Jun 30, 2022 | 9.45 Mn |
| Mar 31, 2022 | 10.01 Mn |
| Dec 31, 2021 | 3.40 Mn |
| Sep 30, 2021 | 3.54 Mn |
| Jun 30, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.11 Mn |